‘A Political Gimmick’: Expert on China’s Row With Pfizer

A highly anticipated COVID-19 drug from the United States is coming away empty-handed from sales talks with virus-hit China. Chinese officials say the American firm that makes it was charging too much. But is the Chinese regime really unable to afford it? An expert says the deal isn’t so simple.